Essential Thrombocythemia (ET) Market Report 2025

The essential thrombocythemia (ET) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to the rising number of essential thrombocythemia cases, an increase in sickle cell anemia cases, higher investment in research and development, growing awareness among healthcare professionals, and the increasing popularity of related drugs.

The essential thrombocythemia (ET) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to rising awareness and early diagnosis of essential thrombocythemia, greater availability of hematology testing, a growing geriatric population, increased healthcare expenditure, and rising federal funding. Key trends during this period include technological advancements, genetic profiling, novel targeted therapies, advancements in telemedicine, and strategic collaborations.

The increasing adoption of personalized medicine is expected to drive the growth of the essential thrombocythemia (ET) market. Personalized medicine tailors treatment and prevention strategies based on an individual’s genetic makeup, lifestyle, and environmental factors. This approach is becoming more popular due to advancements in genomics, biotechnology, and data analytics, which enable more precise diagnostics and targeted therapies. In the case of essential thrombocythemia, personalized medicine allows for therapies tailored to genetic mutations, enhancing treatment accuracy and improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, compared to just six in 2022. As a result, the rising adoption of personalized medicine is fueling the growth of the ET market.

Companies operating in the essential thrombocythemia market are increasingly focused on developing novel therapeutics, including Phase 3 clinical trials for bomedemstat, to improve treatment efficacy, patient outcomes, and expand the range of available therapies. These late-stage trials assess the safety and effectiveness of bomedemstat, an LSD1 inhibitor, for patients requiring advanced treatment options. For instance, in August 2024, Merck & Co. Inc., a U.S.-based pharmaceutical company, announced the launch of Shorespan-007, a Phase 3 clinical trial of bomedemstat for treating essential thrombocythemia. The trial targets patients who have not received previous cytoreductive therapy. Recruitment for the trial has begun, and patient enrollment is currently underway.

In January 2023, Merck & Co. Inc. acquired Imago BioSciences Inc. for $1.35 billion to strengthen its hematology portfolio. This acquisition allows Merck to enhance its offerings for essential thrombocythemia and other blood-related disorders by integrating Imago BioSciences' innovative therapies. Imago BioSciences specializes in developing treatments for essential thrombocythemia, bolstering Merck’s position in the development of targeted therapies for hematologic diseases.

Major players in the essential thrombocythemia (et) market are Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Bayer AG, Bristol Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Fresenius Kabi AG, Incyte Corporation, Vifor Pharma Management AG, Bio-Techne Corporation, Argenx SE, AOP Orphan Pharmaceuticals AG, Orchard Therapeutics plc, Medunik USA., and Kartos Therapeutics Inc.

North America was the largest region in the essential thrombocythemia (ET) market in 2024. The regions covered in essential thrombocythemia (ET) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the essential thrombocythemia (ET) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets in the bone marrow. This condition increases the risk of blood clots, bleeding complications, and potential progression to myelofibrosis or leukemia. Ongoing monitoring and treatment are required to manage symptoms and prevent complications.

The main treatment options for essential thrombocythemia (ET) include interferon, anagrelide, hydroxyurea, and aspirin. Interferon refers to a group of proteins produced by the immune system that help modulate immune responses and inhibit abnormal cell growth. Diagnostic methods for ET include blood tests, bone marrow biopsies, gene mutation analysis, and other procedures. These are used by various end users, including hospitals, research organizations, and specialty clinics.

The essential thrombocythemia (ET) market research report is one of a series of new reports that provides essential thrombocythemia (ET) market statistics, including the essential thrombocythemia (ET) industry global market size, regional shares, competitors with the essential thrombocythemia (ET) market share, detailed essential thrombocythemia (ET) market segments, market trends, and opportunities, and any further data you may need to thrive in the essential thrombocythemia (ET) industry. This essential thrombocythemia (ET) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The essential thrombocythemia (ET) market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and management services, and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The essential thrombocythemia (ET) market also includes sales of diagnostic products, therapeutic medications, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.